|
Match
|
Document |
Document Title |
|
|
7625866 |
Concentrate of a factor VIII:C-containing von Willebrand factor and the process relating thereto
The invention relates to a concentrate and a process for producing a factor VIII:C-containing von Willebrand factor by fractional precipitation from a liquid comprising factor VIII:C and von...
|
|
|
7576181 |
Method of administering porcine B-domainless fVIII
The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against...
|
|
|
7560107 |
Modified factor VIII
Modified porcine factor VIII is disclosed in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs,...
|
|
|
7557188 |
Methods of treating blood coagulation disorders using a pharmaceutical preparation comprising vWF propeptide
Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWF propeptide as well as a method for producing such a preparation.
|
|
|
7521210 |
Method for large-scale production of polypeptide in eukaryote cells and a culture vessel suitable therefor
The invention provides a method for large-scale production of a polypeptide, such as a Factor VII or Factor VIIa polypeptide, in eukaryote cells, such as mammalian cells, contained in a culture...
|
|
|
7507540 |
Catalytic anti-factor VIII allo-antibodies
A method is disclosed of determining the presence of catalytic anti-Factor VIII allo-antibodies capable of degrading Factor VIII in a mammal, and of characterising the cleavage sites in said Factor...
|
|
|
7323442 |
Agents for alleviating symptoms accompanied by inflammation
The present invention provides agents for alleviating symptoms resulting from inflammation, which have an activity to alleviate inflammatory symptoms caused by bacterial infection, particularly...
|
|
|
7300922 |
Modulators of pharmacological agents
The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a...
|
|
|
7247707 |
Albumin-free factor VIII formulations
A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of...
|
|
|
7244825 |
Dried blood factor composition trehalose
A stable blood factor composition contains a stabilising amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.
|
|
|
7220836 |
Dried blood factor composition comprising trehalose
A stable blood factor composition contains a stabilising amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.
|
|
|
7211559 |
Factor VIII compositions and methods
The present invention provides methods of increasing the half-life and/or specific activity of factor VIII. More specifically, the invention provides methods of increasing the half-life and/or...
|
|
|
7211558 |
Compositions and methods for the treatment of hemophilia A
Improved materials and methods for the treatment of Hemophilia A are provided.
|
|
|
7205278 |
Stabilized proteins with engineered disulfide bonds
The present invention relates to methods of introducing one or more cysteine residues into a polypeptide which permit the stabilization of the polypeptide by formation of at least one bond,...
|
|
|
7199223 |
Polymer-factor VIII moiety conjugates
Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are...
|
|
|
7166709 |
Haemostatically active preparation containing vWF and method for the production thereof
A process for preparing a hemostatically active preparation containing von Willebrand factor (vWF) from a fraction of human plasma by chromatographic purification of a vWF-containing plasma...
|
|
|
7122634 |
Modified factor VIII
Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor...
|
|
|
RE39321 |
Supplemented and unsupplemented tissue sealants, methods of their production and use
This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds,...
|
|
|
7041635 |
Factor VIII polypeptide
The application discloses Factor VIII polypeptides comprising internal deletions of amino acids within the area of residues 741 to 1689, wherein the thrombin cleavage sites at about 741 and about...
|
|
|
7015193 |
Compositions and methods to control bleeding
Disclosed are compositions for treating blood coagulation disorders and allows for manipulation of the blood coagulation cascade. More particularly the invention, relates to compositions for...
|
|
|
7005502 |
Pharmaceutical preparation comprising vWF propeptide
Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWf propeptide as well as a method for producing such a prepartion.
|
|
|
6967239 |
Method of filtering viruses from a factor VIII solution
Method for preparing a factor VIII solution that is essentially free of viruses and essentially devoid of vWF (von Willebrand factor) and factor VIII-vWF complexes by (a) obtaining a starting...
|
|
|
6951655 |
Pro-micelle pharmaceutical compositions
The present invention provides pro-micelle compositions comprising a pharmaceutically active agent encapsulated with a membrane of esterified C 12 -C 18 fatty acids. In the mammalian intestine,...
|
|
|
6946279 |
THROMBIN DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, ANHYDROTHROMBIN DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, PLATELET AGGLUTINATION-INDUCING COMPOSITIONS, METHOD OF INDUCING PLATELET AGGLUTINATION, CLINICAL TEST REAGENTS, CLINICAL TEST METHOD, THROMBOSIS INHIBITORS, ADSORBENT AND PROCESS FOR PRODUCING THE SAME
A thrombin derivative having a lowered fibrinogen activity, a process for producing thereof, an anhydrothrombin derivative having a lowered fibrinogen activity, and a process for producing thereof...
|
|
|
6930087 |
Pharmaceutical composition comprising factor VIII and neutral liposomes
A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and substantially neutral colloidal particles. The particles...
|
|
|
6924151 |
Stable factor VIII/vWF-complex
There are disclosed a stable factor VIII/vWF-complex, particularly comprising high-molecular vWF multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation...
|
|
|
6919311 |
Factor VII polypeptide having factor VII:C activity
Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding...
|
|
|
6887852 |
Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer
Disclosed is a lyophilized preparation of recombinant factor VIII used as a therapeutic preparation of hemophilia A. The lyophilized preparation of recombinant factor VIII is prepared by performing...
|
|
|
6878811 |
Substance with antithrombotic activity and method for detecting glycokallidin
A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a...
|
|
|
6869790 |
Preparation of DNA encoding factor XIIIA
The cDNA which codes for factor XIIIa has been isolated using a cDNA bank from human placenta and probes constructed on the basis of the amino acid sequence of factor XIIIa peptide fragments. It is...
|
|
|
6780411 |
Tissue sealant compositions
Tissue sealant compositions containing human recombinant fibrinogen, human recombinant factor XIII and human recombinant thrombin. Also disclosed are preferred formulations and uses therefore.
|
|
|
6759216 |
Glycosylated, low antigenicity low immunogenicity factor VIII
The development of inhibitory antibodies to blood coagulation factor VIII (fVIII) results in a severe bleeding tendency. These antibodies arise in patients with hemophilia A (hereditary fVIII...
|
|
|
6737405 |
Stabilized protein preparation and process for its preparation
A stabilized protein preparation is described which contains no antithrombin III and is protected against loss of activity during pasteurization by the addition of stabilizers which comprise one or...
|
|
|
6737074 |
Methods of separating cells, transplanting cells and engineering tissue using fibrin microbeads
The present invention provides fibrin microbeads that are biologically active and comprise extensively cross-linked fibrin(ogen), and a method for preparing the fibrin microbeads. The present...
|
|
|
6693173 |
Method to remove citrate and aluminum from proteins
A method is provided for removing citrate, aluminum, and other multivalent ions and contaminants from proteins by adjusting the pH of a solution containing the protein to a pH from about 7 to about...
|
|
|
RE38431 |
Methods of production and use of liquid formulations of plasma proteins
The present invention relates to the preparation and use of liquid formulations of plasma proteins, particularly blood coagulation factors. More specifically, the present invention relates to...
|
|
|
6683159 |
Methods for producing factor VIII proteins
Methods are provided for purification of Factor VIII polypeptides by immunoaffinity chromatography and ion exchange chromatography, in which the eluate from the immunoaffinity column is diluted...
|
|
|
6605222 |
Method for producing a factor VIII/von Willebrand factor complex
The invention relates to a method for the production of factor VIII:C/von Willebrand factor complex from plasma or a plasma fraction by chromatography in a cation exchanger, wherein the factor...
|
|
|
6582603 |
Method for purifying thrombin substrate and/or inhibitors or method for eliminating the same
A method for the refinement of a thrombin substrate, characterized by comprising therein a step of affinity chromatography formed by using an affinity adsorbent having as a ligand a thrombin or...
|
|
|
6579723 |
Method of recovering highly purified vWF or factor VIII/vWF-complex
A method for purifying factor VIII/vWF complex or free vWF by immunoaffinity chromatography in a form suitable for use as a medicament. Factor VIII/vWF complex or free vWF is recovered from an...
|
|
|
6566504 |
Process for viral inactivation of lyophilized blood proteins
A process for inactivating viral contaminants of lyophilized Factor VIII by heat is provided. The process comprises forming a stable complex between the Factor VIII and a cyclodextrin in an aqueous...
|
|
|
6552172 |
Fibrin nanoparticles and uses thereof
The present invention provides fibrin nanoparticles having a mean diameter of 200-2000 nm. The present invention provides also methods for preparing fibrin particles of various sizes, including...
|
|
|
6531577 |
von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
A high-purity von Willebrand factor preparation, a process for making it, and use of the preparation and compositions containing it for the treatment of disorders are disclosed.
|
|
|
6504012 |
Method for preparing dual virally inactivated immune globulin for intravenous administration
A process for producing an intravenously-administrable gamma globulin solution substantially free of contaminating viruses by fractionating an impure gamma globulin solution and then treating the...
|
|
|
6503731 |
Fibrin microbeads prepared from fibrinogen, thrombin and factor XIII for binding cells
Fibrin microbeads are prepared containing extensively cross-linked fibrin (ogen) without using glutaraldehyde. The fibrin microbeads are preferably prepared by containing an aqueous solution...
|
|
|
6500646 |
Cell membrane-directed drugs
Drugs in which peptides having affinity specific for phospholipids, preferably those which are contained in the constituents of lipid bilayers forming the surface layers of cells and of which the...
|
|
|
6489290 |
Antiplatelet agent
This invention combines the unique antiplatelet effects of S-nitrosothiols and the antiadhesive properties of fragments of von Willebrand (vWF) in the A1 domain to provide unique molecules that...
|
|
|
6447774 |
Stabilized protein preparations for a tissue adhesive
A tissue adhesive is described, which contains three separate components, i.e., a stabilized, essentially fibrinogen-free protein preparation that is of storage-quality in liquid state and...
|
|
|
6358703 |
Expression system for factor VIII
This invention describes a protein-free production process for proteins having factor VIII procoagulant activity. The process includes the derivation of stable human cell clones with high...
|
|
|
6346513 |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
Novel polypeptides having Factor VIII activity are provided as well as compositions and methods for their preparation. The polypeptides comprise derivatives and fragments of Factor VIII and have...
|